|
|
|
|
LEADER |
00000cam a2200000Ia 4500 |
001 |
EBSCO_ocn811139143 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m eo d |
007 |
cr cn||||m|||a |
008 |
120926s2012 nyua foab 000 0 eng d |
040 |
|
|
|a CaBNvSL
|b eng
|e pn
|c J2I
|d J2I
|d E7B
|d OCLCQ
|d N$T
|d NYMPP
|d CUS
|d CDX
|d IDEBK
|d UMI
|d OCLCO
|d UV0
|d YDXCP
|d DEBBG
|d DEBSZ
|d COO
|d OCLCQ
|d OCLCF
|d CHVBK
|d OCLCQ
|d D6H
|d AGLDB
|d CNCGM
|d OCLCO
|d JBG
|d OCLCO
|d MERER
|d OCLCO
|d OCLCQ
|d ESU
|d OCLCQ
|d RRP
|d OCLCA
|d UPM
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d VNS
|d OCLCO
|d STF
|d OCLCO
|d VTS
|d OCLCQ
|d INT
|d TOF
|d OCLCQ
|d M8D
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCA
|d UKSSU
|d UIU
|d OCLCO
|d OCL
|d OCLCQ
|
019 |
|
|
|a 843077259
|a 858681730
|
020 |
|
|
|a 9781606504086
|q (electronic bk.)
|
020 |
|
|
|a 1606504088
|q (electronic bk.)
|
020 |
|
|
|a 9781606504222
|q (electronic bk.)
|
020 |
|
|
|a 1606504223
|q (electronic bk.)
|
020 |
|
|
|a 1283896060
|q (ebk)
|
020 |
|
|
|a 9781283896061
|q (ebk)
|
020 |
|
|
|z 9780791860038
|q (print)
|
020 |
|
|
|z 0791860035
|q (print)
|
024 |
7 |
|
|a 10.1115/1.860038
|2 doi
|
028 |
5 |
2 |
|a 860038
|b asme
|
029 |
1 |
|
|a AU@
|b 000052281361
|
029 |
1 |
|
|a CHBIS
|b 010609649
|
029 |
1 |
|
|a CHVBK
|b 358271789
|
029 |
1 |
|
|a DEBBG
|b BV041049043
|
029 |
1 |
|
|a DEBBG
|b BV042793670
|
029 |
1 |
|
|a DEBSZ
|b 404318606
|
029 |
1 |
|
|a DEBSZ
|b 472760955
|
029 |
1 |
|
|a NZ1
|b 15190467
|
029 |
1 |
|
|a NZ1
|b 16077724
|
035 |
|
|
|a (OCoLC)811139143
|z (OCoLC)843077259
|z (OCoLC)858681730
|
037 |
|
|
|a 420856
|b MIL
|
050 |
|
4 |
|a R857.N34
|b N253 2012
|
060 |
|
4 |
|a 2013 A-196
|
060 |
|
4 |
|a WL 358
|
072 |
|
7 |
|a MED
|x 108000
|2 bisacsh
|
082 |
0 |
4 |
|a 610.284
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Nanoparticles and brain tumor treatment /
|c Gerardo Caruso [and others].
|
246 |
1 |
|
|i Available from some providers with title:
|a Application of nanoparticles in brain tumor treatment
|
260 |
|
|
|a New York, N.Y. :
|b ASME ;
|a [New York, N.Y.] (222 East 46th Street, New York, NY 10017) :
|b Momentum Press,
|c 2012.
|
300 |
|
|
|a 1 online resource (viii, 99 pages) :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Biomedical and nanomedical technologies
|
588 |
0 |
|
|a Online resource; title from PDF title page (Momentum Press, viewed April 12, 2013).
|
504 |
|
|
|a Includes bibliographical references (pages 81-99).
|
505 |
0 |
|
|a 1. Introduction.
|
505 |
8 |
|
|a 2. Glioma biology -- 2.1 Invasion and angiogenesis.
|
505 |
8 |
|
|a 3. Blood-brain barrier -- 3.1 Blood-brain barrier physiology -- 3.2 Blood-brain barrier transport systems.
|
505 |
8 |
|
|a 4. Nanomedicine and nanotechnology -- 4.1 Nanoparticle drug delivery -- 4.1.1 Nanoparticle distribution -- 4.1.2 Nanoparticle functionalization -- 4.1.3 Nanoparticle targeting -- 4.2 Nanomedicine and cancer -- 4.3 Nanomedicine and toxicity.
|
505 |
8 |
|
|a 5. Nanoparticle technologies -- 5.1 Polymeric and polymer-drug conjugate nanoparticles -- 5.2 Micelle nanoparticles -- 5.3 Liposomes -- 5.4 Gold and silver nanoparticles -- 5.5 Metal oxide -- 5.6 Magnetic nanoparticles -- 5.7 Carbon nanotubes -- 5.8 Fullerenes -- 5.9 Peptides nanoparticles -- 5.10 Silica nanoparticles -- 5.11 Quantum dots -- 5.12 Dendrimers.
|
505 |
8 |
|
|a 6. Nanomedicine applications in brain tumors -- 6.1 Brain tumor drug targeting -- 6.1.1 Systemic approaches -- 6.1.2 Physiological approaches -- 6.1.2.1 Receptor-mediated transcytosis -- 6.1.2.2 Adsorptive-mediated transcytosis -- 6.1.2.3 Efflux pump inhibition -- 6.1.2.4 Cell-mediated drug transport -- 6.1.3 Direct CNS approaches -- 6.1.3.1 Intracerebral routes -- 6.1.4 Drug modifications and prodrugs.
|
505 |
8 |
|
|a 7. Experimental studies.
|
505 |
8 |
|
|a 8. Conclusions -- References.
|
520 |
3 |
|
|a Despite progresses in surgery, radiotherapy, and in chemotherapy, an effective curative treatment of gliomas does not yet exist. Mortality is still close to 100% and the average survival of patients with GBM is less than 1 year. The efficacy of current anti-cancer strategies in brain tumors is limited by the lack of specific therapies against malignant cells. Besides, the delivery of the drugs to brain tumors is limited by the presence of the blood brain barrier. The oncogenesis of gliomas is characterized by several biological processes and genetic alterations, involved in the neoplastic transformation. The modulation of gene expression to more levels, such as DNA, mRNA, proteins and transduction signal pathways, may be the most effective modality to down-regulate or silence some specific gene functions. Gliomas are characterized by extensive microvascular proliferation and a higher degree of vasculature. In malignant gliomas targeted therapies efficacy is low. In this complex field, it seems to be very important to improve specific selective drugs delivery systems. Drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB. Nanotechnology could be used both to improve the treatment efficacy and to reduce the adverse side effects.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Nanomedicine.
|
650 |
|
0 |
|a Nanoparticles.
|
650 |
|
0 |
|a Brain
|x Tumors
|x Treatment.
|
650 |
|
0 |
|a Nanotechnology.
|
650 |
|
2 |
|a Brain Neoplasms
|x therapy
|
650 |
|
2 |
|a Nanomedicine
|
650 |
|
2 |
|a Nanoparticles
|
650 |
|
6 |
|a Nanoparticules.
|
650 |
|
6 |
|a Cerveau
|x Tumeurs
|x Traitement.
|
650 |
|
6 |
|a Nanomédecine.
|
650 |
|
7 |
|a MEDICAL
|x Instruments & Supplies.
|2 bisacsh
|
650 |
|
7 |
|a Nanotechnology.
|2 fast
|0 (OCoLC)fst01032639
|
650 |
|
7 |
|a Brain
|x Tumors
|x Treatment.
|2 fast
|0 (OCoLC)fst00837687
|
650 |
|
7 |
|a Nanomedicine.
|2 fast
|0 (OCoLC)fst01744350
|
650 |
|
7 |
|a Nanoparticles.
|2 fast
|0 (OCoLC)fst01032624
|
653 |
|
|
|a Nanomedicine
|
653 |
|
|
|a Nanotechnology
|
653 |
|
|
|a Nanoparticles
|
653 |
|
|
|a Nanoparticles in Brain Tumor Treatment
|
653 |
|
|
|a Nanoparticle Drug Delivery
|
653 |
|
|
|a Nanoparticle Targeting
|
653 |
|
|
|a Blood-Brain Barrier
|
653 |
|
|
|a Glioma
|
653 |
|
|
|a Astrocytoma
|
653 |
|
|
|a Glioblastoma
|
653 |
|
|
|a Brain Tumor
|
653 |
|
|
|a Glioma Treatment
|
653 |
|
|
|a Brain Tumor Drug Targeting
|
653 |
|
|
|a Angiogenesis
|
653 |
|
|
|a Polymeric
|
653 |
|
|
|a Nanoparticles and Brain Tumors
|
653 |
|
|
|a Carbon Nanotubes and Brain Tumors
|
653 |
|
|
|a Fullerenes and Brain Tumors
|
653 |
|
|
|a Silica Nanoparticles and Brain Tumors
|
653 |
|
|
|a Micelle Nanoparticles and Brain Tumors
|
653 |
|
|
|a Liposome and Brain Tumors
|
700 |
1 |
|
|a Caruso, Gerardo.
|
776 |
0 |
8 |
|i Print version:
|t Nanoparticles and brain tumor treatment.
|d New York : ASME Press : Momentum Press, ©2012
|z 9780791860038
|w (DLC) 2012289797
|w (OCoLC)809616811
|
830 |
|
0 |
|a Biomedical & nanomedical technologies.
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=501120
|z Texto completo
|
938 |
|
|
|a Coutts Information Services
|b COUT
|n 24444258
|
938 |
|
|
|a ebrary
|b EBRY
|n ebr10605115
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 501120
|
938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n cis24444258
|
938 |
|
|
|a Momentum Press
|b NYMP
|n 9781606504222
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 9728798
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 11669335
|
994 |
|
|
|a 92
|b IZTAP
|